orantinib has been researched along with Benign Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (70.59) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Yang, J; Zaware, N | 1 |
| Aftab, DT; Bentzien, F; Chen, J; Cheng, W; Co, EW; Engst, S; Goon, L; Kim, MH; Klein, RR; Lamb, P; Le, DT; Mac, M; Nuss, JM; Parks, JJ; Qian, F; Rodriquez, M; Stout, TJ; Till, JH; Tsuhako, AL; Won, KA; Wu, X; Xu, W; Yakes, FM; Yu, P; Zhang, W; Zhao, Y | 1 |
| Kasak, L; Kauts, ML; Loog, M; Neuman, T; Piirsoo, A; Piirsoo, M; Tints, K; Uusen, P | 1 |
| Arioka, H; Murakami, H; Shimoyama, T; Tamura, T; Ueda, Y; Yamada, Y; Yamamoto, N | 2 |
| Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL | 1 |
| Alileche, A | 1 |
| Ledbetter, S; Pratt, BM; Teicher, BA; Walter-Yohrling, J | 1 |
| Erber, R; Groth, G; Hammes, HP; Katsen, AD; Kerger, H; Menger, MD; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
| Abbruzzese, JL; Charnsangavej, CA; Davis, D; Faria, SC; Herbst, R; Hess, K; Hicks, M; Jackson, EF; Madden, T; McConkey, D; Scholz, C; Xiong, HQ | 1 |
| Giaccone, G; Hoekman, K; Kok, A; Kuenen, BC; Pinedo, HM; Ruijter, R; Schalkwijk, C | 1 |
| Fu, A; Hallahan, DE; Huamani, J; Kim, DW | 1 |
| Gianni, L; Grasselli, G; Ielmini, N; Lladò, A; Locatelli, A; Marimon, I; Marsoni, S; Sessa, C; Trigo, J; Viganò, L | 1 |
| Abdollahi, A; Debus, J; Hauser, K; Huber, PE; Lipson, KE; Roth, A; Timke, C; Weber, KJ; Zieher, H | 1 |
| Kuwano, M; Ono, M | 1 |
| Fabbro, D; Manley, PW | 1 |
| Blanke, CD; Corless, CL; Druker, BJ; Heinrich, MC | 1 |
3 review(s) available for orantinib and Benign Neoplasms
| Article | Year |
|---|---|
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1 | 2001 |
Su-6668. SUGEN.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoles; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Structure-Activity Relationship | 2001 |
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasms; Oxindoles; Piperazines; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles | 2002 |
5 trial(s) available for orantinib and Benign Neoplasms
| Article | Year |
|---|---|
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Plasminogen Activator Inhibitor 1; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A | 2011 |
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles | 2011 |
A phase I surrogate endpoint study of SU6668 in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Endpoint Determination; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Oxindoles; Propionates; Pyrroles; Time Factors; Tomography, X-Ray Computed | 2004 |
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles | 2005 |
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Humans; Indoles; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein Binding; Pyrroles | 2006 |
9 other study(ies) available for orantinib and Benign Neoplasms
| Article | Year |
|---|---|
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Design; Humans; Indoles; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.
Topics: Animals; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Cytochrome P-450 CYP3A; Drug Design; Female; Half-Life; Humans; Indoles; Lung; Mice; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Rats; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |
Protein kinase inhibitor SU6668 attenuates positive regulation of Gli proteins in cancer and multipotent progenitor cells.
Topics: Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation, Developmental; Hedgehog Proteins; Humans; Indoles; Kruppel-Like Transcription Factors; Leukocytes, Mononuclear; Mice; Multipotent Stem Cells; Neoplasms; Nuclear Proteins; Oxindoles; Propionates; Protein Serine-Threonine Kinases; Pyrroles; Signal Transduction; Transcription Factors; Transforming Growth Factor beta; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2014 |
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines | 2002 |
Interleukin-2 and cancer: critical analysis of results, problems and expectations.
Topics: Cytokines; Humans; Immunotherapy; Indoles; Interleukin-2; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Interleukin-2 | 2003 |
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Fibroblasts; Humans; Immunohistochemistry; Indoles; Metalloproteases; Neoplasm Invasiveness; Neoplasms; Oxindoles; Paclitaxel; Propionates; Protease Inhibitors; Pyrroles; Stromal Cells | 2003 |
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2006 |
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Flow Cytometry; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Radiotherapy; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2008 |